Screener
Bioventus BVS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | June 27, 2026 | December 31, 2025 |
|---|---|---|
| Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of June 27, 2026 and December 31, 2025 | 16 | 16 |
| Additional paid-in capital | 527,925 | 520,851 |
| Accumulated deficit | (298,375) | (334,929) |
| Accumulated other comprehensive loss | (1,328) | (1,900) |
| Total stockholders’ equity attributable to Bioventus Inc. | 228,306 | 184,105 |
| Noncontrolling interest | 49,106 | 44,342 |
| Total stockholders’ equity | 277,412 | 228,447 |
| Total liabilities and stockholders’ equity | $673,346 | $683,559 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's total equity?
- Bioventus (BVS) reported total equity of $228.31M in Q2 2026.
- How has Bioventus's total equity changed year-over-year?
- Bioventus's total equity increased by 41.6% year-over-year, from $161.24M to $228.31M.
- What is the long-term trend for Bioventus's total equity?
- Over 4 years (2021 to 2025), Bioventus's total equity has grown at a -20.4% compound annual growth rate (CAGR), from $458.92M to $184.11M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Bioventus's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude